Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. (5th July 2018)

• Record Type: Journal Article
• Authors: Fackrell, Robin; Carroll, Camille B; Grosset, Donald G; Mohamed, Biju; Reddy, Prashanth; Parry, Miriam; Chaudhuri, Kallol Ray; Foltynie, Tom
• Is Part Of: Neurodegenerative disease management. Volume 8:Number 5(2018)
• Page Start: 349
• Page End: 360
• Publication Date: 2018-07-05
• Subjects: opicapone -- Parkinson's disease -- safinamide; Nervous system -- Degeneration -- Periodicals; 616.8
• DOI: 10.2217/nmt-2018-0020
• Languages: English
• ISSNs: 1758-2024

Abstract

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.